Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.69 +5.0%	$0.79	$0.38 ▼ $115.57	$7.79M	0.71	1.71 million shs	111,132 shs
BPTS Biophytis		$13.37	$8.05 ▼ $168.80	$2.89M	1.05	7,291 shs	18,500 shs
IBIO iBio	$0.57 -2.3%	$0.77	$0.56 ▼ $6.89	$9.47M	0.6	1.40 million shs	226,184 shs
TAOX Synaptogenix	$8.34 +12.9%	$0.00	$1.84 ▼ $11.98	$10.27M	1.87	290,647 shs	421,122 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-6.60%	-9.18%	-21.83%	+30.74%	-99.12%
BPTS Biophytis	0.00%	0.00%	0.00%	0.00%	0.00%
IBIO iBio	-1.33%	-7.42%	-28.03%	-26.71%	-62.42%
TAOX Synaptogenix	+19.97%	+13.87%	+738,999,900.00%	+738,999,900.00%	+738,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	3.3974 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	1.9
BPTS Biophytis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.1741 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	52,134.47% Upside
BPTS Biophytis	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	772.45% Upside
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BPTS, IBIO, TAOX, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
BPTS Biophytis	N/A	N/A	N/A	N/A	($17.29) per share	N/A
IBIO iBio	$375K	25.25	N/A	N/A	$1.41 per share	0.41
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	$298.12	3.83	N/A	N/A	N/A	N/A	-994.63%	N/A
BPTS Biophytis	-$18.43M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
TAOX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
BPTS Biophytis	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
BPTS Biophytis	N/A	0.72	0.72
IBIO iBio	0.05	1.76	1.76
TAOX Synaptogenix	N/A	72.59	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
BPTS Biophytis	0.05%
IBIO iBio	7.90%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
BPTS Biophytis	3.70%
IBIO iBio	0.58%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
BPTS Biophytis	22	351,000	338,000	Not Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A

BPTS, IBIO, TAOX, and AEON Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTS, IBIO, TAOX, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.69 +0.03 (+4.96%)

Closing price 03:59 PM Eastern

Extended Trading

$0.68 -0.01 (-1.48%)

As of 07:54 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Biophytis NASDAQ:BPTS

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

iBio NYSE:IBIO

$0.57 -0.01 (-2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.00 (+0.51%)

As of 07:50 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Synaptogenix NASDAQ:TAOX

$8.34 +0.95 (+12.86%)

As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time